The moral limits to federal funding for kidney disease.
In the current era of cost-containment, Congress may reconsider its support for the End-Stage Renal Disease Program. Substantial reductions in funding for this program could be made by eliminating non-beneficial, marginally beneficial, and relatively inefficient modes of treatment. These measures, however, will only postpone the inevitable day when clearly beneficial treatment must be withheld.
Moskop
J C
JC
D030861:Capitalism; D003363:Cost Control / Q000639:trends; D035082:Federal Government; D005380:Financing, Government / Q000191:economics*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy*; D016030:Kidney Transplantation; D009014:Morals; D018579:Patient Selection; D006435:Renal Dialysis / Q000191:economics; D040841:Resource Allocation; D018570:Risk Assessment; D026712:Value of Life